USP7 (Ubiquitin Specific Peptidase 7)

A deubiquitinating enzyme regulating p53, MDM2, and other key cellular pathways; implicated in neurodevelopmental disorders and cancer.

Gene Information Card

Symbol USP7
Full Name Ubiquitin Specific Peptidase 7
Gene Type Protein coding
Chromosomal Location 16p13.2
NCBI Gene ID 7874 ncbi.nlm.nih.gov/gene/7874
Ensembl ID ENSG00000138685
UniProt ID Q93009
OMIM ID 602519
HGNC ID 12630
Aliases HAUSP, TEF1, CGI-11

Description

USP7 (Ubiquitin Specific Peptidase 7), also known as HAUSP (Herpesvirus-Associated Ubiquitin-Specific Protease), is a deubiquitinating enzyme that removes ubiquitin from target proteins, thereby regulating their stability and function. It plays a critical role in the p53/MDM2 pathway, DNA damage response, epigenetic regulation, and immune signaling. Mutations in USP7 are associated with neurodevelopmental disorders and various cancers.

Disease Associations

Disease category Pathophysiological mechanism Genomic evidence
Neurodevelopmental disorder with hypotonia, behavioral abnormalities, and seizures (NEDHBS) Loss-of-function mutations in USP7 impair deubiquitination of substrates such as p53 and MDM2, disrupting neuronal development and synaptic function. ClinVar, OMIM #616901
Prostate cancer USP7 overexpression stabilizes MDM2, promoting p53 degradation and tumor progression. COSMIC, PMID: 26921392
Multiple myeloma USP7 deubiquitinates and stabilizes the oncoprotein MYC, enhancing proliferation. COSMIC, PMID: 27565344
Colorectal cancer USP7 overexpression correlates with poor prognosis; regulates β-catenin and p53 pathways. COSMIC, PMID: 25329317

Expression Profile

Tissue Expression
Tissue nTPM level
Brain (cerebral cortex) 18.5 Medium
Testis 15.2 Medium
Lung 12.8 Medium
Liver 10.1 Low
Heart 8.3 Low
Cell Line Expression
Cell Line nTPM Notes
HEK 293 (embryonic kidney) 22.4 High expression
HeLa (cervical carcinoma) 19.7 High expression
K562 (leukemia) 14.1 Medium expression
HepG2 (hepatocellular carcinoma) 11.3 Low expression
Data source:Human Protein Atlas(proteinatlas.org)

Mutations & Variants

Hotspot Mutations
Variant Type Frequency Functional Description
c.208C>T (p.Arg70*) Nonsense <0.01% Loss of function; associated with NEDHBS
c.512G>A (p.Arg171Gln) Missense <0.01% Loss of function; reduced deubiquitinase activity
c.2155C>T (p.Arg719Trp) Missense <0.01% Loss of function; impaired substrate binding
c.2633A>G (p.Tyr878Cys) Missense <0.01% Loss of function; altered protein stability
Mutation functional classification

Loss of Function (LOF)

Most pathogenic mutations in USP7 are loss-of-function, leading to reduced deubiquitinase activity and dysregulation of substrates like p53, MDM2, and FOXO4. These are primarily associated with neurodevelopmental disorders.

Gain of Function (GOF)

Gain-of-function mutations are rare but may involve overexpression or increased catalytic activity, observed in some cancers where USP7 stabilizes oncoproteins.

Dominant Negative (DN)

Dominant-negative effects have been proposed for certain missense mutations that retain partial activity but disrupt normal USP7 complex formation, though evidence is limited.

Gene Ontology (GO)

• cysteine-type deubiquitinase activity • protein deubiquitination
• ubiquitin-dependent protein catabolic process • regulation of protein stability
• DNA damage response • chromatin remodeling
• negative regulation of apoptotic process • viral process

Pathways

• p53 pathway (Reactome: R-HSA-3700989)
• MDM2-mediated degradation of p53 (Reactome: R-HSA-6804756)
• Deubiquitination (Reactome: R-HSA-5688426)
• Regulation of FOXO transcription factors (Reactome: R-HSA-9614085)

Protein Summary

USP7 is a 1102-amino acid deubiquitinating enzyme containing a TRAF-like domain, a catalytic USP domain, and multiple ubiquitin-like domains. It removes ubiquitin from specific substrates, including p53, MDM2, FOXO4, and PTEN, thereby regulating their stability and cellular localization. USP7 is essential for embryonic development, DNA repair, and immune responses. Its dysregulation contributes to cancer and neurodevelopmental disorders.

Related Products

Product name Cat.No. Species Gene ID
USP7 Knockout HAP1 Cell Line EDC08040 Human 7874 Details Get a Quote

Biological Process

Gene Expression and Regulation: A Complete Technical Map from Mechanism to Validated Cell Models

Promoters, Enhancers and 3D Genome Organization: How to Validate Regulatory Relationships with Editing and Interference Tools

Enhancer–Gene Pair Validation: A Complete Technical Roadmap from Candidate Element to Publishable Evidence

CRISPR Deletion vs CRISPRi for Regulatory Elements: Choosing by Evidence Requirement

Building Reporter Cell Lines for Quantitative Regulatory Readouts

TAD Boundaries and Insulators: What They Constrain and What They Do Not Prove

Super-Enhancers and Cell Identity: Design Strategies for Functional Validation

Validating Transcription Factor Binding Sites: From ChIP Peaks to Functional Evidence

From GWAS Signal to Causal Variant: Functional Validation of Non-Coding Risk Loci

Enhancer Redundancy and Shadow Enhancers: Designing Controls That Catch Compensation

Core Promoter Elements: Dissecting Initiator, TATA and CpG-Island Promoters

Single-Cell Multi-Omics for Mapping Regulatory Elements in Heterogeneous Tissues

How Many Candidate Enhancers Can a Single CRISPRi Screen Test?

What Fragment Size Should Be Deleted When Removing an Enhancer?

How to Design sgRNAs for Enhancer Deletion

What Effect Size Counts as Biologically Meaningful in Enhancer Studies?

What Controls Are Required for a Regulatory Element Knockout?

How to Confirm a TAD Boundary Is Functional

Can ATAC-seq Alone Identify Functional Enhancers?

What Is a Shadow Enhancer, and Why Does It Break Your Screen?

How to Report Negative Results in Regulatory Element Studies

Distance Window or TAD Boundary: Which Constraint Matters More?

DNA Methylation, Histone Marks and Chromatin State: Selecting and Validating Epigenome-Editing Tools

CRISPRoff, dCas9-TET and dCas9-p300: A Practical Comparison for Targeted Epigenetic Editing

How Long Does Epigenetic Silencing Last? Stability, Inheritance and Reversibility

DNMT and TET Knockout Cell Lines: What Phenotypes to Expect and How to Verify Them

Reading Chromatin Accessibility: From ATAC-seq Peaks to Functional Hypotheses

Histone Modification Writers, Readers and Erasers: A Knockout Map

Assessing Off-Target Effects in Epigenetic Editing

Single-Cell Epigenomics: scATAC-seq and scChIP-seq in Development and Disease

Spatial Epigenomics: Mapping Modifications In Situ

Epigenetic Clocks and cfDNA Methylation as Biomarkers

Imprinting and Parent-of-Origin Expression: Why Allele-Specific Regulation Matters

What Is CRISPRoff and How Does It Differ From dCas9-KRAB?

How Stable Is Epigenetic Silencing Across Cell Divisions?

Which Cell Line Is Best for Studying DNA Methylation?

How to Validate a DNMT1 Knockout Clone

What Is a Differentially Methylated Region (DMR)?

Do Epigenetic Edits Create Off-Target Methylation Changes?

How to Link ATAC-seq Changes to Gene Expression Causality

What Is Histone Lactylation and Why Does It Matter?

How to Design a Single-Cell ATAC-seq Experiment

Can Epigenetic Editing Restore a Silenced Gene?

lncRNA, miRNA and RNA Modification: A Complete Path from Function Prediction to Phenotype Validation

Why lncRNA Knockouts Often Show No Phenotype — and How to Design Around It

lncRNA Functional Validation: Knockout vs Knockdown vs Antisense Oligonucleotides

m6A Writers, Readers and Erasers: Mapping and Testing RNA Modification Function

miRNA–Target Validation: Evidence Beyond Luciferase Reporter Assays

RNA-Binding Protein Screens: Design, Readouts and Hit Prioritization

Alternative Splicing Regulation: Isoform-Level Validation Strategies

Circular RNA Biology: Detection, Function and Experimental Pitfalls

RNA Localization and the Spatial Regulation of Translation

Why Does an lncRNA Knockout Often Show No Phenotype?

Knockdown vs Knockout for lncRNA: Which Is More Informative?

How Long a Fragment Should Be Deleted for an lncRNA Knockout?

Which m6A Antibody Should I Use for MeRIP-seq?

What Is the Difference Between RIP-seq and CLIP-seq?

How to Validate a miRNA Target Without a Luciferase Assay

How Many Isoforms Must an Alternative Splicing Study Cover?

Is Circular RNA Detection Reliable Across Platforms?

How to Verify RNA Localization Experimentally

What Proportion of Annotated lncRNAs Are Functional?

CRISPR Knockout, Knock-In, Activation and Screening: A Strategy Matrix for Regulatory Research

Knockout, CRISPRi or Base Editing? A Six-Dimension Decision Matrix

Genome-Wide CRISPR Screening: Library Coverage, MOI and Readout Design

Perturb-seq and Single-Cell Screens: Linking Perturbation to Transcriptional Programs

Essential Genes and Lethal Phenotypes: How to Study What You Cannot Knock Out

Base Editing and Prime Editing in Regulatory Research: When Precision Beats Deletion

Quantifying Editing Efficiency and Off-Target Events: A Practical Framework

Choosing a Cas9 Variant and Delivery Format for Your Cell Type

Multiplex Editing and Temporal Control of Gene Regulation

How Much Library Coverage Is Enough for a Genome-Wide Screen?

What MOI Should I Use for a Lentiviral CRISPR Library?

How to Screen a Non-Proliferative Phenotype

How to Study an Essential Gene with CRISPR

What Is the Difference Between Base Editing and Prime Editing?

How to Measure Knockout Efficiency in a Cell Pool

How to Design a Multiplex Knockout Experiment

Which Cas9 Variant Works Best for AAV Delivery?

What Is a Safe-Harbor Locus for Knock-In?

How Many Clones Must Be Screened to Confirm a Homozygous Knockout?

From Pathway to Model: Validation Paradigms in Cancer, Neuro, Immune and Metabolic Research

Oncogene Dependency and Synthetic Lethality: Building the Right Validation Model

Enhancer Dysregulation in Neurodegeneration: Lessons from Glial and Neuronal Models

CAR-T and ADCC Target Validation: Engineering Immune Cell Lines for Functional Assays

Hippo, WNT and PI3K: Validating Pathway Nodes with Knockout Cell Lines

Drug Target Validation: A Standardized Workflow from Hit to Model

Metabolic Pathway Enzymes: Building Loss-of-Function Models

Gene Editing in iPSC and Organoids: Constraints, Timelines and Readouts

Disease-Associated Non-Coding Variants: From Risk Locus to Cellular Phenotype

How to Validate Pathway Activation After a Knockout

How Long Does iPSC Gene Editing Take?

How to Edit Organoids Without Disrupting Their Structure

Which Cell Line Models ADCC Most Reliably?

How to Build a Synthetic Lethality Screen

What Is a Good Model for Enhancer Dysregulation in Neurons?

How to Validate a Drug Target Before Committing to a Programme

Why Does My Knockout Cell Line Lose the Phenotype After Passaging?

How to Choose Between Human and Mouse Cell Models

What QC Documentation Should Accompany a Custom Cell Line?

Gene Knockout Feasibility Self-Assessment: Ten Constraints That Decide the Project

Pathway-to-Model Reference Chart: Key Genes × Recommended Cell Models

Working with Hard-to-Transfect Cells: A Delivery Strategy Guide

How We Validate Knockout Clones: PCR, Sanger and Western Blot in Combination

Custom Knockout Cell Line Service: Strategy Design, Single-Cell Cloning and Triple Validation

Stable dCas9-KRAB and Cas9 Expression Cell Lines

Knock-In Reporter Cell Lines for Regulatory Readouts

Genome-Wide CRISPR Library Screening Service

Services Comparison: In-House vs CRO vs Off-the-Shelf Cell Lines

Epigenetic Editing Enters the Clinic: What It Means for Research Models

AI Sequence Models in Regulatory Genomics: Hype, Reality and Where They Help

Live-Cell Imaging Rewrites the Rules of Transcriptional Regulation

Spatial and Single-Cell Multi-Omics: The Next Validation Frontier

From CRISPR Screens to Programmable Medicine: A Five-Year Outlook

Contact Us
*
*
*
How did you hear about us: